Abstract
In chronic inflammatory diseases such as rheumatoid arthritis (RA), systemic inflammation appears as an independent risk factor, contributing to increased cardiovascular mortality. This high cardiovascular mortality reveals the existence of accelerated atherosclerosis, the pathogenesis of which may be associated with traditional risk factors such as smoking, hypertension, dyslipidemia, deterioration of insulin sensitivity, and less traditional risk factors such as hyperhomocysteinemia, inflammatory conditions and endothelial dysfunction. Control of systemic inflammation theoretically provides a means of preventing this higher cardiovascular mortality among RA patients. In this review we address the question of the impact of anti-rheumatic drugs currently used in RA, such as non-steroidal anti-inflammatory drugs (e.g. non-selective or cyclooxygenase-2 selective inhibitors), steroidal anti-inflammatory drugs (glucocorticoids), traditional disease-modifying anti-rheumatic drugs (e.g. methotrexate) or biologics (e.g. anti-tumour necrosis factor alpha anti-tumour necrosis factor alpha) on cardiovascular diseases in RA patients. We also discuss the specific mechanisms involved in the differential cardiovascular effects of these therapeutic agents.
Keywords: Rheumatoid arthritis, cardiovascular diseases, disease-modifying anti-rheumatic drugs, glucocorticoids, nonsteroidal anti-inflammatory drugs, biologics
Current Vascular Pharmacology
Title: Impact of Traditional Therapies and Biologics on Cardiovascular Diseases in Rheumatoid Arthritis
Volume: 6 Issue: 3
Author(s): Jean-Frederic Boyer, Alain Cantagrel and Arnaud Constantin
Affiliation:
Keywords: Rheumatoid arthritis, cardiovascular diseases, disease-modifying anti-rheumatic drugs, glucocorticoids, nonsteroidal anti-inflammatory drugs, biologics
Abstract: In chronic inflammatory diseases such as rheumatoid arthritis (RA), systemic inflammation appears as an independent risk factor, contributing to increased cardiovascular mortality. This high cardiovascular mortality reveals the existence of accelerated atherosclerosis, the pathogenesis of which may be associated with traditional risk factors such as smoking, hypertension, dyslipidemia, deterioration of insulin sensitivity, and less traditional risk factors such as hyperhomocysteinemia, inflammatory conditions and endothelial dysfunction. Control of systemic inflammation theoretically provides a means of preventing this higher cardiovascular mortality among RA patients. In this review we address the question of the impact of anti-rheumatic drugs currently used in RA, such as non-steroidal anti-inflammatory drugs (e.g. non-selective or cyclooxygenase-2 selective inhibitors), steroidal anti-inflammatory drugs (glucocorticoids), traditional disease-modifying anti-rheumatic drugs (e.g. methotrexate) or biologics (e.g. anti-tumour necrosis factor alpha anti-tumour necrosis factor alpha) on cardiovascular diseases in RA patients. We also discuss the specific mechanisms involved in the differential cardiovascular effects of these therapeutic agents.
Export Options
About this article
Cite this article as:
Boyer Jean-Frederic, Cantagrel Alain and Constantin Arnaud, Impact of Traditional Therapies and Biologics on Cardiovascular Diseases in Rheumatoid Arthritis, Current Vascular Pharmacology 2008; 6 (3) . https://dx.doi.org/10.2174/157016108784911975
DOI https://dx.doi.org/10.2174/157016108784911975 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lignans' Potential in Pre and Post-onset Type 2 Diabetes Management
Current Diabetes Reviews An Impact of Lifestyle Modification on Insulin Resistance in Hypertensive Patients with Metabolic Syndrome
Current Hypertension Reviews Atrial Tachycardias Occurring Late After Open Heart Surgery
Current Cardiology Reviews Growth Restriction: Etiology, Maternal and Neonatal Outcome. A Review
Current Women`s Health Reviews New Insights on the Beneficial Effects of the Probiotic Kefir on Vascular Dysfunction in Cardiovascular and Neurodegenerative Diseases
Current Pharmaceutical Design Pathophysiology and Treatment of Obesity Hypertension
Current Pharmaceutical Design Intravascular Targeting of a New Anticoagulant Heparin Compound
Cardiovascular & Hematological Disorders-Drug Targets MicroRNA-155 Functions as a Negative Regulator of RhoA Signaling in TGF-β-induced Endothelial to Mesenchymal Transition
MicroRNA Pharmacological and Surgical Therapy for Primary Postpartum Hemorrhage
Current Pharmaceutical Design Pulmonary Hypertension in Cardiac Surgery
Current Cardiology Reviews Leptin as a Novel Therapeutic Target for Immune Intervention
Current Drug Targets - Inflammation & Allergy The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?
Current Vascular Pharmacology Algorithms and Criteria for Transcatheter Aortic Valve Replacement Patient Selection: Current Status and Future Trends
Current Pharmaceutical Design Oral Appliances Improve Sleep Quality in Japanese Patients with Obstructive Sleep Apnea
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design A Validated UPLC Method Used for the Determination of Trandolapril and its Degradation Products as per ICH Guidelines
Current Pharmaceutical Analysis Hyperhomocysteinemia and Endothelial Dysfunction
Current Hypertension Reviews An Evidence-Based Systematic Review of Stevia by the Natural Standard Research Collaboration
Cardiovascular & Hematological Agents in Medicinal Chemistry Down-Regulation of Angiogenic Inhibitors: A Potential Pathogenic Mechanism for Diabetic Complications
Current Diabetes Reviews Vasoactive Compounds in the Neonatal Period
Current Medicinal Chemistry